SCHEMBL25946358

SCHEMBL25946358

CC(C)(C)c1cccnc1OCc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.46
MAPK14 Q16539 1/20 0.46
RXRA P19793 1/20 0.46
RXRB P28702 1/20 0.46
RXRG P48443 1/20 0.46
L3MBTL1 Q9Y468 3/20 0.45
ATP4A P20648 1/20 0.45
ATP4B P51164 1/20 0.45
MAPK1 P28482 2/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.43
HTT P42858 1/20 0.43
P2RY1 P47900 4/20 0.43
CNR2 P34972 3/20 0.42
CNR1 P21554 2/20 0.42
CYP3A4 P08684 1/20 0.42
MEN1 O00255 1/20 0.42
NPC1 O15118 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12922790 0.79 MEN1 (0.42) L3MBTL1MAPK1ALDH1A1HPGDTSHR
SCHEMBL23995716 0.78 P2RY1 (0.33) RXRARXRBRXRGP2RY1ALOX5AP
SCHEMBL23490625 0.77 L3MBTL1 (0.53) LTA4HMAPK14RXRARXRBRXRG
SCHEMBL821369 0.76 TDP1 (0.50) ALDH1A1P2RY1ATMMAPTTDP1
SCHEMBL14803553 0.76 P2RY1 (0.44) MAPK1ALDH1A1LMNAHPGDHTT
SCHEMBL24215198 0.76 L3MBTL1 (0.53) LTA4HMAPK14L3MBTL1ATP4AATP4B
SCHEMBL8526782 0.75 LTA4H (0.66) LTA4HMAPK14L3MBTL1MAPK1ALDH1A1
SCHEMBL9446223 0.75 RXRA (0.71) LTA4HMAPK14RXRARXRBRXRG
SCHEMBL23344983 0.75 SLC6A2 (0.41) ALDH1A1LMNAHTTP2RY1MEN1
SCHEMBL6371918 0.75 SSTR4 (0.45) P2RY1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858916-B2 GLP-1 receptor agonists and uses thereof PFIZER INC. (US) 2024-01-02 US disclosed
US-20230357208-A1 MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS Epizyme, Inc. (US) 2023-11-09 US disclosed
US-11685732-B2 MYST family histone acetyltransferase inhibitors Epizyme, Inc. (US) 2023-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357208-A1 MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS EP300, KAT2A, KAT6A LTA4H 3066/4885MAPK14 2720/4885RXRA 2590/4885
US-11858916-B2 GLP-1 receptor agonists and uses thereof GLP1R, GIPR, GCGR LTA4H 1293/4885MAPK14 2639/4885RXRA 299/4885
US-11685732-B2 MYST family histone acetyltransferase inhibitors EP300, KAT2A, KAT6A LTA4H 3066/4885MAPK14 2720/4885RXRA 2590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.